Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

A Pro-Inflammatory Gene Signature Characterizes a Better Risk Aged AML Patient Group in ECOG-ACRIN Cancer Research Group's Clinical Trial E3999

Blood (2023) 142 (Supplement 1): 4326.

https://doi.org/10.1182/blood-2023-179569

Published: 2023

Journal Articles

ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients

Guillermo Garcia-Manero, Kimo Bachiashvili, Harshad Amin, Elie Traer, Daniel A. Pollyea, David A. Sallman, Aref Al-Kali, Larry D. Cripe, Jesus G Berdeja, Elizabeth A. Griffiths, Sanjay R Mohan, Yuri Sano, Aram Oganesian, Harold N. Keer, Abdulraheem Yacoub

Blood (2022) 140 (Supplement 1): 1112–1114.

https://doi.org/10.1182/blood-2022-156512

Published: 2022

Journal Articles

P62SQSTM1 Affects Interacting Substrates MDM2, MDMX and Casein Kinase 1alpha to Yield Protection of Beta-Catenin Along with p53 Silencing for Refractory AML

Justin Layer, Sravanti Rangaraju, Santhosh Pasupuleti, Larry D. Cripe, Hamid Sayar, Katie J Sargent, Jill Weisenbach, Huda S. Salman, G. David Roodman, Linsey Mayo, Reuben Kapur, Utpal P Dave', H. Scott Boswell

Blood (2022) 140 (Supplement 1): 11546–11547.

https://doi.org/10.1182/blood-2022-156329

Published: 2022

Journal Articles

A Retrospective Observational Real-World Study of the Characteristics, Genomic Analysis, Treatment Patterns and Outcomes of Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the United States

John C. Byrd, Jennifer L Gatz, Larry D. Cripe, , Cynthia Lim Louis, Alice S. Mims, Uma Borate, Ashley O. Yocum, Theophilus Gana, Amy Burd

Blood (2021) 138 (Supplement 1): 3383.

https://doi.org/10.1182/blood-2021-153926

Published: 2021

Journal Articles

Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials

Chezi Ganzel, Kevin Roopcharan, Zhuoxin Sun, Jacob M. Rowe, Hugo F Fernandez, Elisabeth M. Paietta, Selina M. Luger, Hillard M Lazarus, Larry D Cripe, Dan Douer, Peter H. Wiernik, Martin S. Tallman, Mark R. Litzow

Blood (2021) 138 (Supplement 1): 690.

https://doi.org/10.1182/blood-2021-149208

Published: 2021

Journal Articles

Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations

Sravanti Rangaraju, MBBS, Silvia Marino, PhD, G. David Roodman, MD PhD, Larry D. Cripe, MD, Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Katie J Sargent, RN, Hamid Sayar, MD MSc, Heiko Konig, MD PhD, Reuben Kapur, PhD, H. Scott Boswell, MD

Blood (2019) 134 (Supplement_1): 5051.

https://doi.org/10.1182/blood-2019-124384

Published: 2019

Journal Articles

Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML

Sravanti Rangaraju, MBBS, Silvia Marino, PhD, Daniela Nicoleta Petrusca, PhD, Larry D Cripe, MD, Katie J Sargent, RN, G. David Roodman, MD PhD, Hamid Sayar, MD MSc, Baskar Ramdas, PhD, Lakshmi Reddy Palam, PhD, Rajasubramaniam Shanmugam, PhD, Adriana Rogozea, Heiko Konig, MD PhD, Reuben Kapur, PhD, H. Scott Boswell, MD

Blood (2018) 132 (Supplement 1): 3949.

https://doi.org/10.1182/blood-2018-99-111181

Published: 2018

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study

Blood (2018) 132 (Supplement 1): 2170.

https://doi.org/10.1182/blood-2018-99-118383

Published: 2018

Journal Articles

Genomic Landscapes in Elderly AML

Blood (2017) 130 (Supplement 1): 404.

https://doi.org/10.1182/blood.V130.Suppl_1.404.404

Published: 2017

Journal Articles

Final Results of Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Poor-Risk Cytogenetics

Antoine N Saliba, MD, H. Scott Boswell, MD, Larry D Cripe, MD, Mohammad Issam Abu Zaid, MBBS, Jill Weisenbach, RN, OCN, Hamid Sayar, MD MSc

Blood (2017) 130 (Supplement 1): 3897.

https://doi.org/10.1182/blood.V130.Suppl_1.3897.3897

Published: 2017

Journal Articles

Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience

Chezi Ganzel, Larry D. Cripe, MD, Zhouxin Sun, Hugo F. Fernandez, MD, Peter A Cassileth, MD, Dan Douer, MD, Jacob M. Rowe, MD, Elisabeth Paietta, PhD, Michael O'Connell, Peter H Wiernik, John M. Bennett, MD, Mark R Litzow, MD, Selina Luger, MD, Hillard M. Lazarus, MD, Martin S. Tallman, MD

Blood (2015) 126 (23): 1315.

https://doi.org/10.1182/blood.V126.23.1315.1315

Published: 2015

Journal Articles

The Combination of the Novel Syk Inhibitor TAK659 with Decitabine Exerts Synergistic Cytotoxic Effects Against FLT3/ITD Mutated Acute Myeloid Leukemia Cells

Edwin Stage, MS, Magdalena Czader, MD PhD, Heather O'Leary, PhD, H. Scott Boswell, MD, Larry D. Cripe, MD, Hamid Sayar, MD, Cedric Dos Santos, PhD, Mark J. Levis, MD PhD, Heiko Konig, MDPhD

Blood (2015) 126 (23): 4928.

https://doi.org/10.1182/blood.V126.23.4928.4928

Published: 2015

Journal Articles

Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Monosomy 5, 7, or Complex Cytogenetics

Mohammad Abu Zaid, MBBS, H. Scott Boswell, MD, Larry D. Cripe, MD, Yan Liu, PhD, Jill Weisenbach, BS, Hamid Sayar, MD MS

Blood (2014) 124 (21): 976.

https://doi.org/10.1182/blood.V124.21.976.976

Published: 2014

Journal Articles

High-Risk AML, Including Flt3ITD+, Exhibits Resistance To Conventional Cytarabine Induction Associated With Diminished ENT1 and p16INK Expression: Evidence For Epigenetic Repression and HDAC Inhibitor Modulated De-Repression

H. Scott Boswell, MD, Sushil Gupta, Rui Gao, PhD, Katie J Sargent, Larry D. Cripe, MD, Mehdi Nassiri, MD, Hamid Sayar, MD, Yan Liu, PhD

Blood (2013) 122 (21): 2525.

https://doi.org/10.1182/blood.V122.21.2525.2525

Published: 2013

Journal Articles

Pilot Study Of Erlotinib In Patients With Acute Myeloid Leukemia

Hamid Sayar, MD, MSc, Magdalena Czader, MD, PhD, Chirag Amin, MD, Mary Cangany, Bsc, Larry D Cripe, MD

Blood (2013) 122 (21): 5037.

https://doi.org/10.1182/blood.V122.21.5037.5037

Published: 2013

Journal Articles

Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML

Blood (2012) 120 (21): 1875.

https://doi.org/10.1182/blood.V120.21.1875.1875

Published: 2012

Journal Articles

Single-Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (AML): Validation in Two Independent Sample Sets From ECOG and SWOG Trials.

Alessandra Cesano, M.D., Ph.D., Cheryl L Willman, MD, Kenneth J. Kopecky, PhD, Urte Gayko, Ph.D., Santosh Putta, Ph.D., Brent Louie, Ph.D., Matt Westfall, Ph.D., Norman Purvis, Ph.D., David Spellmeyer, PhD, Carol Marimpietri, James Hackett, Ph.D., Jing Shi, Elisabeth Paietta, PhD, Martin S. Tallman, MD, Larry D Cripe, MD, Susan K. Atwater, MD, Frederick R. Appelbaum, MD, Jerald P. Radich, MD

Blood (2012) 120 (21): 2489.

https://doi.org/10.1182/blood.V120.21.2489.2489

Published: 2012

Journal Articles

The Impact of Obesity on the Presentation & Outcome of Adult Acute Myeloid Leukemia (AML) - ECOG Studies E1900 & E3999

James M. Foran, MD, FRCPC, Zhuoxin Sun, PhD, Hugo F. Fernandez, MD, Larry D Cripe, MD, Rhett P Ketterling, MD, Janis Racevskis, PhD, Selina M. Luger, MD, Elisabeth Paietta, PhD, Hillard M. Lazarus, MD, FACP, Mark R. Litzow, MD, Martin S. Tallman, MD

Blood (2011) 118 (21): 2568.

https://doi.org/10.1182/blood.V118.21.2568.2568

Published: 2011

Journal Articles

Single Cell Network Profiling (SCNP) Functionally Characterizes FLT3 Pathway Deregulation in Non-M3 Acute Myeloid Leukemia (AML) and Provides Prognostic Value Independent From Mutational Status

Alessandra Cesano, M.D., Ph.D., Santosh Putta, Ph.D., Kavita Mathi, MD, David B. Rosen, PhD, Urte Gayko, Ph.D., Rachael E. Hawtin, Ph.D., Larry D Cripe, MD, Zhuoxin Sun, PhD, Martin S. Tallman, MD, Elisabeth Paietta, Ph.D.

Blood (2011) 118 (21): 2512.

https://doi.org/10.1182/blood.V118.21.2512.2512

Published: 2011

Journal Articles

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

Blood (2011) 117 (12): 3294–3301.

https://doi.org/10.1182/blood-2010-08-301796

Published: 2011

NARROW

A Pro-Inflammatory Gene Signature Characterizes a Better Risk Aged AML Patient Group in ECOG-ACRIN Cancer Research Group's Clinical Trial E3999

ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients

P62SQSTM1 Affects Interacting Substrates MDM2, MDMX and Casein Kinase 1alpha to Yield Protection of Beta-Catenin Along with p53 Silencing for Refractory AML

A Retrospective Observational Real-World Study of the Characteristics, Genomic Analysis, Treatment Patterns and Outcomes of Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the United States

Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials

Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations

Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML

Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study

Genomic Landscapes in Elderly AML

Final Results of Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Poor-Risk Cytogenetics

Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience

The Combination of the Novel Syk Inhibitor TAK659 with Decitabine Exerts Synergistic Cytotoxic Effects Against FLT3/ITD Mutated Acute Myeloid Leukemia Cells

Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Monosomy 5, 7, or Complex Cytogenetics

High-Risk AML, Including Flt3ITD+, Exhibits Resistance To Conventional Cytarabine Induction Associated With Diminished ENT1 and p16INK Expression: Evidence For Epigenetic Repression and HDAC Inhibitor Modulated De-Repression

Pilot Study Of Erlotinib In Patients With Acute Myeloid Leukemia

Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML

Single-Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (AML): Validation in Two Independent Sample Sets From ECOG and SWOG Trials.

The Impact of Obesity on the Presentation & Outcome of Adult Acute Myeloid Leukemia (AML) - ECOG Studies E1900 & E3999

Single Cell Network Profiling (SCNP) Functionally Characterizes FLT3 Pathway Deregulation in Non-M3 Acute Myeloid Leukemia (AML) and Provides Prognostic Value Independent From Mutational Status

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only